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ABSTRACT
 
Diabetes mellitus is an endocrine disorder and 
affecting millions of people. It remains latent and its 
secondary obstacles leads to the mortality and 
morbidity. Various metal such as arsenic, beryllium, 
cadmium and nickel have been linked with the 
occurrence of diabetes mellitus in peoples exposed to 
these elements. Some elements like iron and copper 
are crucial minerals that are necessary for a variety 
of molecules to maintain their normal structures, 
functions of cells to existence, grow, and multiply. 
The homeostasis of iron and copper is coordinated 
regulation by different proteins concerned in uptake, 
excretion and intracellular storage or transferring. 
This study connected airborne levels of these metals 
with diabetes mortality. The lowest air levels detected 
were beryllium and cadmium, with nickel showing the 
highest levels. This supported diabetes mortality 
effects of air pollution and correlating arsenic, 
beryllium, cadmium and nickel with diabetes 
incidence. Although, iron is essential but it can be 
toxic in high amounts. Iron is a transit mineral can 
generate various reactive oxygen or nitrogen species 
so abnormal metabolism of iron can lead to numerous 
chronic pathogenesis. Oxidative stress is one of the 
main contributing factors for diabetes and diabetic 
problems. Iron overload may increases risks of 
insulin resistance and diabetes. 
 
Keywords: Air pollution, diabetes mellitus; heavy 
metals 
 
 
INTRODUCTION 
Diabetes mellitus is an endocrine disorder, 
affecting millions of individuals. It is a key 
cause of morbidity in the developed 
countries. The WHO reported that about 
300 million individuals will have diabetes 
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mellitus by the year 2025 [1]. It affects 
people of all ages and ethnic groups [2]. 
Diabetes influences about 5% of the world 
population and treatment of diabetes 
without any side effects is still a challenge 
to the medical system [3]. Diabetes is a 
heterogeneous group of disorders that lead 
to rise of glucose level in the blood. 
Chronic hyperglycemia and risk of the 
producing problems are the two joint 
properties which have held the concept of 
diabetes together. Trace elements roles 
mainly as catalysts in enzyme systems; 
some metallic ions, like iron and copper, 
contribute in oxidation-reduction reaction 
in energy metabolisms. Iron, as a part of 
hemoglobin and myoglobin and plays a 
crucial role in the transport of oxygen. All 
trace elements are toxic if consumed at 
adequately high amounts for long times. 
The distinction between toxic intakes and 
optimal intakes for essential trace elements 
is great for some elements but is much 
smaller for others. Trace elements are also 
present in food in organic and inorganic 
form. In human body only 5% of body 
weight is mineral matter, vital to all mental 
and physical processes and for well-being. 
They are very important factors in keeping 
all physiological activities, are constituents 
of the teeth, bones, tissues, muscle, blood 
and nerve cells. They may act as catalysts 
for various biological reactions within the 
body, they are crucial for transmission of 
messages through the central nervous 
system, digestion and metabolism or 
utilization of all nutrients in foods. 
Micronutrients, minerals and trace 
elements are very important for the human 
body. They have various roles in 
metabolism and body functions. They are 
essential for the proper function of cells, 
tissues, and organs. Some minerals, such 
as iron, make up part of many proteins and 
enzymes in the body. Minerals also play a 
role in the building up of muscle and bone 
and are important for normal body growth. 
It is well established that several trace 
elements are of great importance in a 
number of biological processes, mostly 
through their action as activators or 
inhibitors of enzymatic reactions, by 
competing with other elements and 
proteins for binding sites, by influencing 
the permeability of cell membranes, or 
through other mechanisms. It is therefore 
reasonable to assume that these minerals 
would also exert an action, either directly, 
or indirectly, on the pancreas. Disorders of 
mineral metabolism are sometimes passed 
from parents to their children through 
genes. Other medical conditions, such as 
starvation, diarrohea, or alcoholism, can 
cause mineral metabolism problems. 
 
The association between environmental 
heavy exposure and different chronic 
diseases like depression, hypertension and 
cardiovascular diseases [4]. Heavy metals 
have no biological or nutritional value. 
However, one regular topic is the 
relationship between heavy metal exposure 
and the progress of diabetes mellitus 
[5−19], an effect that might involve direct 
cytotoxicity or autoimmunity [20]. The 
effects on diabetes might also impact renal 
disease by these metals, particularly 
cadmium [15]. Diabetes mellitus is a 
disease connected with demographic 
factors such as socioeconomic status and 
race. It is necessary to elucidate the 
consequences of heavy metal exposure at 
the population level to the prevalence and 
mortality of diabetes [9−12]. The 
associations between environmental 
contaminates and diabetes mellitus. The 
arsenic and cadmium levels were higher in 
diabetic subjects than age-matched non-
diabetic controls in hair, blood and urine 
[5]. Similarly, adverse effects on 
pancreatic islet cells from arsenic and 
cadmium [6]. Higher rates of diabetes 
mellitus in populations exposed to high 
levels of arsenic in drinking water [9, 10]. 
Inadequate evidence to support arsenic as 
playing a causal role in diabetes [12], 
some other studies has supported this 
hypothesis [7−12]. The evidence linking 
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beryllium to diabetes is likely via this 
element’s ability to induce an autoimmune 
T-cell response, ultimately attacking islet 
cells and other organs [17, 18]. In fact, 
beryllium up-regulates programmed death-
1 expression on beryllium-Specific 
CD4+T Cells, a pathway leading to the 
onset of diabetes [19, 20]. Arsenic, 
cadmium has been linked to diabetes 
mellitus [5, 6]. A report demonstrated a 
relationship between high urinary levels of 
cadmium with impaired glucose tolerance 
[14]. The evidence supporting the link 
between cadmium exposure and diabetes, 
finding that cadmium reduces insulin 
levels, is directly cytotoxic on the pancreas 
and may be a factor in development of this 
disease [15]. Potentially connecting 
cadmium to diabetes mortality, cadmium 
is likely toxic to nerve terminals, and thus 
may exacerbate complications from this 
disease [16]. The nickel effect on diabetes 
mellitus has bit inconsistent. Nickel is 
known to avert the development of 
streptozotocin-induced diabetes in rats and 
preventing hyperglycemia [21, 22]. 
Additionally, no relationship between 
nickel blood levels and diabetes in humans 
[23, 24]. By contrast, in concert with nitric 
oxide, nickel can induce hyperglycemia in 
rats [8].  
 
Minerals and trace elements may exert 
protective or scavenging effects, as well as 
being essential components of several key 
enzymes in intracellular antioxidant 
defense [25]. Their deficiency, or excess, 
may contribute to derangement of the pro-
oxidant/anti-oxidant balance, and hence to 
the progressive appearance of secondary 
complications as the disease advances. 
Both type I and II diabetes are 
accompanied by alterations in 
micronutrient absorption, tissue uptake, 
and excretion, some in a time-dependent 
fashion. A major effect of these changes 
may be a worsening of the oxidative 
balance, with declining capability to 
combat endogenously produced free 
radicals. Macro and microelements are 
involved in the complex processes of 
development of the secondary 
complications of diabetes mellitus 
affecting many organs. They may be 
integral components of antioxidant 
enzymes (e.g., Cu, in case of superoxide 
dismutase, and Se for Glutathione 
peroxidase), cofactors in a variety of 
enzymatic processes of importance in 
glucose and lipid metabolism (e.g., Cu), or 
potential pro-oxidant catalysts (e.g., Cu, 
Fe). The etiology of diabetes and its 
complications still is not clear, however 
several factors as aging, obesity and 
oxidative damage have been implicated. 
Several micronutrients have beneficial 
effects in healthy subjects and also in 
diabetes [26, 27]. Copper, iron and 
manganese are important components of 
metalloenzymes such as Se–cys containing 
glutathione peroxidase, Cu/Fe cytochrome 
C oxidase and/or different types of 
superoxide dismutases, all of them 
imperative in intra- and extra-cellular 
antioxidant defense [28]. Copper is found 
in the liver, gallbladder, lungs and heart. It 
is essential primarily for the absorption 
and metabolism of iron. A deficiency in 
copper results in the same effects as an 
iron deficiency, such as retarded 
hemoglobin production, general debility, 
limited growth, etc. Some sources have 
estimated about 2 milligrams per day. 
Very few cases of copper depletion have 
been observed in humans. Copper is 
needed for synthesis of hemoglobin, 
proper iron metabolism, and maintenance 
of blood vessels. Copper is an integral part 
of the enzyme copper-zinc superoxide 
dismutase (CuZn SOD); also present in 
other enzymes, including cytochrome 
oxidase, ascorbic acid oxidase, and 
tyrosinases. It is usually found in the red 
blood cells, and in blood plasma. The chief 
supplementary sources of copper are 
seafood, nuts, legumes, green leafy 
vegetables. Insufficient copper has been 
associated with: changes in hair colour and 
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texture, and hair loss; disturbances to the 
nervous system; bone diseases. Serious 
deficiency is rare but can lead to: Menke's 
syndrome.  
Copper has been shown to be elevated in 
experimentally diabetic rats [29]. Iron 
status is little affected by diabetes per se; 
however, because of its role as a catalyst in 
free radical generation, and the given state 
of increased oxidant stress in diabetes, it is 
probably advisable for diabetic individuals 
to avoid excess iron. Hence, this present 
research is mainly focused on the role of 
the following essential trace elements in 
Type I DM and Type II Diabetes mellitus 
conditions: iron, selenium, copper, 
chromium, vanadium and molybdenum. 
Interactions between these trace elements 
and hyperglycemia are also briefly 
considered. Epidemiologic data on the 
relationship between many of the trace 
elements and the incidence of diabetes and 
hypertension are incomplete. Most such 
studies have focused on cadmium, 
chromium, and selenium. Furthermore, 
most of the evidence is not related to 
dietary exposure but focuses, for example, 
on inhalation exposure in the workplace. 
The biochemical role for copper is 
primarily catalytic, with many copper 
metalloenzymes acting as oxidases to 
achieve the reduction of molecular 
oxygen. Many copper metalloenzymes 
have been identified in humans [30]. 
Ferroxidases are copper enzymes found in 
plasma, with a function in ferrous iron 
oxidation (Fe
2+→Fe3+) that is needed to 
achieve iron’s binding to transferring [31]. 
Ferroxidase I, also called ceruloplasmin, is 
the predominant copper protein in plasma 
and may also have antioxidant functions. 
Defects in ceruloplasmin function produce 
cellular iron accumulation, a result that 
supports its ferroxidase role [30]. 
Ferroxidase II is found in human plasma, 
but it may have a role in iron metabolism 
in specific cellular sites. A transmembrane 
copper-containing protein (hephaestin) 
with ferroxidase activity has been 
described [32]. Cytochrome c oxidase is a 
multisubunit enzyme in mitochondria that 
catalyzes reduction of O2 to H2O. This 
establishes a high energy proton gradient 
required for adenosine triphosphate (ATP) 
synthesis. This copper enzyme is 
particularly abundant in tissues of greatest 
metabolic activity including heart, brain, 
and liver. Dopamine β monooxygenase 
uses ascorbate, copper, and O2 to convert 
dopamine to norepinephrine, a 
neurotransmitter, produced in neuronal and 
adrenal gland cells. Dopa, a precursor of 
dopamine, and metabolites used in 
melanin formation are oxidatively 
produced from tyrosine by the copper 
enzyme tyrosinase. α-amidating 
monooxygenase, also called 
peptidylglycine alpha amidating 
monooxygenase, uses copper and 
ascorbate to remove two carbons from a C-
terminal glycine of peptides, thus 
generating an amide. Several peptide 
hormones are posttranslationally modified 
by alpha amidating monooxygenase. 
Copper/zinc superoxide dismutase (Cu/Zn 
SOD) uses two copper atoms for the 
conversion of the superoxide anion (O2
-
) to 
H2O2 and O2. Zinc atoms have a structural 
role in the enzyme [30]. The enzyme is 
localized in the cytosol and, along with the 
mitochondrial manganese-containing form, 
provides a defense against oxidative 
damage from superoxide radicals that, if 
uncontrolled, can lead to other damaging 
reactive oxygen species. Mutations in the 
Cu/Zn SOD gene, which alter the protein’s 
redox behavior, produce amyotrophic 
lateral sclerosis. These are the principal 
copper metalloenzymes found in humans. 
There is substantial documentation from 
animal studies that diets low in copper 
reduce the activities of many of these 
copper metalloenzymes. Activities of some 
copper metalloenzymes have been shown 
to decrease in human copper depletion 
[33]. Physiologic consequences resulting 
from copper deficiency include defects in 
connective tissue that lead to vascular and 
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skeletal problems, anemia associated with 
defective iron utilization, and possibly 
specific aspects of central nervous system 
dysfunction [30]. The immune and cardiac 
dysfunction occurs in experimental copper 
deficiency and the development of such 
signs of deficiency has been demonstrated 
in infants [35]. Iron plays a pathogenic 
role in diabetes and its complications such 
as microangiopathy and atherosclerosis 
[36]. The importance of protein glycation 
is well known in the pathogenesis of 
diabetic vascular complications. Transition 
metals also play a role in protein glycation 
induced by hyperglycemia. Glycated 
proteins possess a substantial attraction for 
the transition metals, and the bound metal 
retains redox activity and contributes to 
catalytic oxidation processes [37]. Thus, 
should similar glycochelates form in vivo, 
reactions mediated by the iron chelates 
could be involved in the vascular 
complications of diabetes [38]. During 
superoxide-dependent formation, more 
reactive radicals such as hydroxyl radical 
(OH•) requires the presence of transition 
metal ions such as copper or iron [39]. 
Although, OH• is highly reactive, its in 
vivo formation is contingent upon the 
availability of physiological iron. 
Interestingly, in the present study, a 
parallel increase in the amount of iron with 
the malondialdehyde release (index of 
oxidative stress) was observed in Type I 
and Type II diabetic patients as compared 
to healthy normal individuals.  
 
Since iron is a reactive metal ion that is 
known to catalyze damage to cellular 
macromolecules caused by oxygen 
radicals, its reduction from Fe
3+
 to the Fe
2+
 
state plays a major role in lipid 
peroxidation process. As the concentration 
of iron increases, it finally accumulates in 
the liver. Ferritin, an iron storage protein 
may function as a source of iron for 
promotion of superoxide-dependent lipid 
peroxidation [39]. The small size of O2-, 
which is generated by xanthine oxidase in 
conjunction with its ability to reduce 
chelated iron, suggests that it is an 
excellent candidate for the mobilization of 
iron from ferritin. All parenteral 
administered iron in excess of the ferritin 
storage mechanism accumulates in the 
liver as hemosiderin. Thus the rise in the 
amount of iron in the serum of the diabetic 
patients might be either due to increased 
release of iron from the body storage depot 
into the systemic circulation or to 
attenuation in the process of storage 
related to oxidative stress. Evidence 
linking iron to diabetic nephropathy 
includes  
 Animal and epidemiological 
investigations,  
 Researches in which an increased 
amount of iron has been demonstrated 
in the kidneys of both animals [40,41] 
and humans [42] with kidney disease, 
 Evidence for higher urinary iron in 
patients with diabetic nephropathy, and  
 The inhibition of progression either by 
an iron-deficient diet or agents that 
bind and eliminate iron (chelators) 
[43−45].  
 
Earlier experimental investigations offer 
extensive proof for the role of iron and 
oxidants in the pathogenesis of diabetic 
nephropathy [46-50]. Oxidative stress 
from factors such as hyperglycemia, 
advanced glycation end products, and 
dyslipidemia contribute to the obtainability 
of intracellular iron that can produce and 
viciously worsen oxidative deterioration 
and renal damage. Iron content in the 
kidney has been demonstrated to be 
amplified in an animal model of diabetes 
[51], and urinary iron excretion is elevated 
early in the course of diabetic renal disease 
in humans [50, 52]. There is substantial 
proof that, once renal insufficiency 
progresses, irrespective of etiology, it 
inclines to headway over time. This has 
been interpreted to show certain common 
pathways for development of kidney 
disorders. Most notably, the pathogenic 
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part of iron in progression is indicated by 
the observation that development can be 
prohibited either by an iron-deficient diet 
or chelators [43−45]. A current 
randomized trial involving 191 patients 
with diabetes, proteinuria, and a decreased 
glomerular filtration rate exhibited that a 
low-iron–available, carbohydrate-
restricted, polyphenol-enriched diet 
compared with a standard protein-
restricted diet had a renoprotective activity 
[53]. Epidemiologic investigations 
[54−56] in explicit iron overload states 
such as transfusional iron overload and 
hemochromatosis have indicated that the 
incidence of coronary heart disease is 
increased [57] and that dietary intake with 
iron chelation recovers cardiovascular 
outcome. Likewise, numerous researches 
have indicated a direct connotation 
between higher iron intake, body iron 
reservoirs, and cardiovascular jeopardy in 
the general population. Elevated intake of 
heme iron is related with augmented 
cardiovascular events [58−61], and 
increased body iron stores are linked with 
myocardial ischemia in a prospective 
epidemiological investigation [62]. 
Reliable and sensitive methods need to be 
developed to precisely measure the 
free/catalytic iron that participates in 
oxidative injury. Iron chelation therapy 
may present a novel way to interrupt the 
cycle of catalytic iron–induced oxidative 
stress and tissue injury and consequent 
release of catalytic iron in diabetes and to 
prevent diabetes-related complications.  
 
Copper has been known to be essential for 
health for more than three quarters of a 
century. Copper functions as a component 
of a number of metalloenzymes acting as 
oxidases to achieve the reduction of 
molecular oxygen. The primary criterion 
used for copper is a combination of 
indicators, including plasma copper and 
ceruloplasmin concentrations, erythrocyte 
superoxide dismutase activity, and platelet 
copper concentration in controlled human 
depletion/repletion studies [63]. There was 
a significant elevation observed in serum 
copper content in Type I and Type II 
diabetic patients as compared to normal 
controls. There is a significant increase in 
the levels of copper in type 1 DM subjects 
when compared to healthy control 
subjects. There is significant increase in 
the levels of copper in type 2 DM subjects 
when compared to healthy control 
subjects. There is significant increase in 
the levels of copper in type 1 DM subjects 
when compared to type 2 DM subjects. 
Elevated level of copper in type I and type 
II diabetes mellitus is a major risk factor 
for the incidence of cardiovascular disease 
[64]. Diabetic patients with vascular 
complications have higher plasma copper 
levels than diabetic patients without 
complications or normal controls [64]. 
Patients with the “metabolic syndrome” 
(patients having common risk factors such 
as obesity, hypertension, glucose 
intolerance, and dyslipidemia) also have 
elevated copper levels [65]. Copper 
overload in diabetes mellitus differs from 
that in Wilson's disease through 
differences in their respective causative 
molecular mechanisms, and resulting 
differences in tissue localization and 
behavior of the excess copper. 
Pathogenetic tissue binding of copper is 
elevated in diabetes. It may well be 
mediated by advanced-glycation end 
product (AGE) modification of susceptible 
amino-acid residues in long-lived fibrous 
proteins, for example, connective tissue 
collagens in locations such as blood vessel 
walls. The copper metabolism becomes 
abnormal after induction of diabetes in rats 
and that the copper chelator trientine, 
given to these animals, alleviated their 
heart failure, improved cardiomyocyte 
structure, and reversed elevations in left 
ventricular collagen and β1 integrin 
without lowering blood glucose. In 
diabetic patients, trientine therapy 
decreased left ventricular hypertrophy 
[63], the beneficial effects of trientine in 
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animal studies of diabetic neuropathy [66]. 
The elevated serum ceruloplasmin levels 
are associated with albuminuria in Korean 
men with type 2 diabetes mellitus [67].  
Reactive oxygen species (ROS) are 
induced under diabetic conditions and are 
likely associated with the development of 
diabetes. It is also known that ROS 
production is facilitated in the presence of 
copper ion through the Fenton reaction 
[68]. Thethe involvement of copper ion in 
the pathogenesis of type 2 diabetes and 
evaluated the potential usefulness of a 
copper chelating agent for the treatment of 
type 2 diabetes [58]. Since, copper ion is 
involved in the development of diabetes, it 
may be a potential therapeutic target for 
diabetes. The biochemical role for copper 
is primarily catalytic, with many copper 
metalloenzymes acting as oxidases to 
achieve the reduction of molecular 
oxygen. Many copper metalloenzymes 
have been identified in humans [69]. 
Copper/zinc superoxide dismutase (Cu/Zn 
SOD) uses two copper atoms for 
conversion of the superoxide anion (O2
-
) to 
H2O2 and O2. Our results also confirmed 
same pattern and showed significant 
enhancement in lipid peroxidation level 
(malondialdehyde release) in diabetic 
conditions. A concomitant decline in 
antioxidant status (FRAP assay) was also 
observed. Several other clinical 
observations deserve further investigation, 
but there is insufficient evidence to link 
them to marginal copper status. Glucose 
tolerance was lower in two of a group of 
eight men consuming 80 μg/day of copper 
than in men consuming higher levels of 
copper [70], but similar observations have 
not been reported at lower intakes of 
copper in other studies. 
 
DISCUSSION 
This study has found an association 
between heavy metals arsenic, beryllium, 
cadmium and nickel air contaminants and 
age adjusted diabetes mellitus mortality 
rates. Although associations between these 
heavy metals arsenic, beryllium, cadmium 
and nickel and diabetes prevalence by the 
high concentrations of these heavy metals 
in the diabetic patient and increase in 
diabetes mortality. Hazardous air 
pollutants-including arsenic, beryllium, 
cadmium and nickel-an analysis of these 
elements’ concentrations based might start 
to mitigate diabetes death for pollutants 
[70, 71]. It is important to note that these 
results are subject to a number of 
limitations. First, although this study con- 
trolled for many county-level risk factors 
for diabetes, it could not control for other 
confounders. Such factors might include 
county level obesity and heart disease 
rates. Additionally this analysis was 
unable to control for other environmental 
toxins known to be associated with 
diabetes (e.g., chromium), nor is it known 
the sources from which these toxins are 
released. In addition, since ecological 
studies compare data at the population 
level, these results cannot be extrapolated 
down to the individual level. For example, 
it could be that no person with diabetes 
who died in a specific county was ever 
exposed to these elevated environmental 
toxins. In spite of the great amount of 
work that has been done on the 
relationships between trace elements and 
diabetes, the evidence is still fragmentary. 
The nature of the correlations—whether it 
is a cause-to-effect relationship or simply a 
statistical association—is still unknown. 
The mechanisms of action are also poorly 
understood. Further clinical investigations 
are needed to elucidate these problems, 
and hence the present study has been taken 
as a contribution to the research activities 
in this field with special emphasize on role 
of minerals in influencing the metabolic 
homeostasis in Type I and Type II diabetes 
[71].  
 
CONCLUSION 
There is suggestive evidence that iron and 
copper plays a pathogenic role in diabetes 
and its complications such as 
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microangiopathy and atherosclerosis. 
Reliable and sensitive methods need to be 
developed to precisely measure the 
free/catalytic iron and copper that 
participates in oxidative injury. Hence 
measuring the levels of iron and copper in 
early age may help to predict the onset of 
diabetes and its secondary complications 
which may postpone the diabetes.  
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